Canada Type 2 Diabetes Mellitus Drugs Market Analysis

Canada Type 2 Diabetes Mellitus Drugs Market Analysis


$ 3999

Canada Type 2 Diabetes Mellitus Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Type 2 Diabetes Mellitus Drugs market is growing globally due to the increasing prevalence of Type 2 diabetes, growing awareness and diagnosis about the disease, advancements in drug therapies, rising geriatric population, government initiatives and healthcare policies, technological advancements in drug delivery, increasing research and development activities and rising healthcare infrastructure. Novo Nordisk, Sanofi, Eli Lilly and Company, Merck & Co., Inc., AstraZeneca, Johnson & Johnson, Boehringer Ingelheim, Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb, Novartis International are the key global market players in type 2 Diabetes Mellitus Drugs Market.

ID: IN10CAPH413 CATEGORY: Pharmaceuticals GEOGRAPHY: Canada AUTHOR: Aneri Parekh

Buy Now

Canada Type 2 Diabetes Mellitus Drugs Market Analysis Summary

Canada Type 2 Diabetes Mellitus Drugs Market is valued at around $2251.2 Mn in 2022 and is projected to reach $4229 Mn by 2030, exhibiting a CAGR of 8.2% during the forecast period 2023-2030.

A chronic metabolic condition called Type 2 Diabetes Mellitus (T2DM) is characterized by excessive blood glucose levels brought on by insulin resistance and insufficient insulin production. It is the most prevalent kind of diabetes and normally appears in adults, however, it can also happen in youngsters. The majority of diabetes cases worldwide are T2DM. When a person has T2DM, their body either generates insufficient insulin or uses it inefficiently. A hormone called insulin controls the metabolism of glucose and enables cells to absorb blood glucose for energy. The body's cells lose their ability to respond to insulin when it occurs, which raises blood glucose levels (hyperglycemia). T2DM is brought on by several variables, such as heredity, obesity, sedentary behavior, poor food, and age. Due to increased insulin resistance, people who are overweight or obese have a higher chance of developing T2DM. Moreover, a history of diabetes in the family. Metformin, Sulfonylureas like glipizide, glyburide, and glimepiride, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors like sitagliptin, saxagliptin, and linagliptin, Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors like canagliflozin and dapagliflozin and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists like liraglutide, exenatide, and dulaglutide are the commonly used drugs. Novo Nordisk, Sanofi, Eli Lilly and Company, Merck & Co., Inc., AstraZeneca, Johnson & Johnson, Boehringer Ingelheim, Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb, Novartis International are the key global market players in type 2 Diabetes Mellitus Drugs Market.

Market Dynamics

Market Growth Drivers

The increasing prevalence of Type 2 diabetes, growing awareness and diagnosis about the disease, advancements in drug therapies, rising geriatric population, government initiatives and healthcare policies, technological advancements in drug delivery, increasing research and development activities, and rising healthcare infrastructure act as market growth drivers.

Market Restraints

High cost of treatment, limited awareness and diagnosis, technological barriers, comorbidities and complex treatment regimens, adherence and compliance issues, side effects and safety concerns act as market growth restraints.    

Competitive Landscape

Key Players

  • ?Novo Nordisk
  • Sanofi
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • AstraZeneca
  • Johnson & Johnson
  • Boehringer Ingelheim
  • Takeda Pharmaceutical Company Limited
  • Bristol-Myers Squibb
  • Novartis International

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For Canada Type 2 Diabetes Mellitus Drugs Market

By Drug Class

  • Biguanides (e.g., Metformin)
  • Sulfonylureas (e.g., Glipizide, Glyburide)
  • Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (e.g., Sitagliptin, Saxagliptin)
  • Sodium-glucose Co-Transporter-2 (SGLT-2) Inhibitors (e.g., Empagliflozin, Canagliflozin)
  • Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists (e.g., Liraglutide, Exenatide)
  • Insulin (various types and formulations)

By Route of Administration

  • Oral medications (tablets, capsules)
  • Injectable medications (subcutaneous or intramuscular injections)
  • Insulin therapy (subcutaneous injections or insulin pump)

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By End-User

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Homecare Settings

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 27 February 2024
Updated by: Riya Doshi

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up